Protocol
10-181
Full Title
High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-Infected Patients (BMT CTN PROTOCOL 0803)(AMC-071)
Purpose
High-dose chemotherapy with autologous stem cell rescue, also known as autologous stem cell transplantation, is fairly standard for patients under age 70 with lymphoma if the first treatment fails to cure them. During autologous stem cell transplantation, the patient’s own stem cells are collected from the blood, frozen, and then given back to the patient after chemotherapy.
However, patients with HIV have some special issues. Some HIV drugs could cause side effects. Some infections could happen at a higher rate. However, studies thus far do not suggest an increased risk of death compared to patients without HIV infection.
This study is being conducted to better define the risks and benefits of high-dose chemotherapy with autologous stem cell rescue in HIV-infected patients with lymphoma. The results of this study will help guide treatment decisions for future patients with HIV.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be infected with HIV and have B-cell or Hodgkin lymphoma that has been treated with one to three prior regimens of chemotherapy.
- Patients must be age 15 or older
For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 212-639-7423.
Disease(s)
AIDS-Associated Cancers
AIDS-Associated Cancers: AIDS-Associated Lymphomas
Blood & Marrow Stem Cell Transplantation: Autologous
Lymphoma
Lymphoma: Hodgkin's Disease
Lymphoma: Non-Hodgkin's Lymphoma
Locations
ClinicalTrials.gov
